- Home
- CTXR vs EPRX Comparison
CTXR vs EPRX Comparison
Compare CTXR & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTXR
- EPRX
- Stock Information
- Founded
- CTXR 2007
- EPRX 2011
- Country
- CTXR United States
- EPRX Canada
- Employees
- CTXR N/A
- EPRX N/A
- Industry
- CTXR Biotechnology: Pharmaceutical Preparations
- EPRX
- Sector
- CTXR Health Care
- EPRX
- Exchange
- CTXR Nasdaq
- EPRX NYSE
- Market Cap
- CTXR 84.9M
- EPRX 85.5M
- IPO Year
- CTXR N/A
- EPRX N/A
- Fundamental
- Price
- CTXR $0.41
- EPRX $2.52
- Analyst Decision
- CTXR Strong Buy
- EPRX
- Analyst Count
- CTXR 2
- EPRX 0
- Target Price
- CTXR $5.00
- EPRX N/A
- AVG Volume (30 Days)
- CTXR 1.1M
- EPRX 6.4K
- Earning Date
- CTXR 08-12-2024
- EPRX 01-01-0001
- Dividend Yield
- CTXR N/A
- EPRX N/A
- EPS Growth
- CTXR N/A
- EPRX N/A
- EPS
- CTXR N/A
- EPRX N/A
- Revenue
- CTXR N/A
- EPRX N/A
- Revenue This Year
- CTXR N/A
- EPRX N/A
- Revenue Next Year
- CTXR N/A
- EPRX N/A
- P/E Ratio
- CTXR N/A
- EPRX N/A
- Revenue Growth
- CTXR N/A
- EPRX N/A
- 52 Week Low
- CTXR $0.34
- EPRX $2.20
- 52 Week High
- CTXR $1.07
- EPRX $3.50
- Technical
- Relative Strength Index (RSI)
- CTXR 38.61
- EPRX N/A
- Support Level
- CTXR $0.34
- EPRX N/A
- Resistance Level
- CTXR $0.41
- EPRX N/A
- Average True Range (ATR)
- CTXR 0.04
- EPRX 0.00
- MACD
- CTXR 0.00
- EPRX 0.00
- Stochastic Oscillator
- CTXR 36.59
- EPRX 0.00
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.